DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 18, 2021, reports on events occurring on May 15, 2021. DarioHealth Corp. (Nasdaq: DRIO) entered into a definitive agreement to acquire PsyInnovations, Inc. (dba wayForward), a behavioral health technology company. The transaction is structured as a merger where PsyInnovations will become a wholly-owned subsidiary of DarioHealth.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the acquisition rather than the company's operational financial results for a specific period.
- Total Merger Consideration: $6.0 million in cash plus up to $24.0 million in common stock.
- Stock Issuance: Approximately 1,138,000 shares of common stock, valued based on a 60-day VWAP of $21.09 per share.
- Earn-Out Provision: Up to $5.0 million of the stock consideration is contingent on behavioral health revenues exceeding a specific threshold in 2022.
- Hold-Back: $3.0 million ($2.75 million in stock, $250,000 in cash) is held back for 18 months to secure indemnification obligations.
- Executive Compensation: Founder Ritvik Singh will receive a non-qualified stock option for 75,000 shares (60,000 time-based vesting, 15,000 performance-based).
Material Changes and Conditions
The filing does not report material changes to prior financial periods as it is a current report on a specific event. The closing of the merger is subject to several conditions, including:
- Accuracy of representations and warranties.
- Compliance with covenants by all parties.
- Approval by holders representing at least 95% of the merger consideration.
- Execution of lock-up, release, and joinder agreements by consenting holders.
Outlook, Risks, and Contingencies
Management intends for the merger to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code. Key contingencies include the satisfaction of closing conditions and the achievement of 2022 revenue targets to trigger the earn-out. The stock issued to holders is subject to a lock-up period, releasing in five equal installments every three months, commencing six months after the closing date.
Investor Verification Checklist
- Verify the final closing date and whether the 95% holder approval threshold was met.
- Confirm the exact number of shares issued based on the final closing price versus the $21.09 VWAP used for estimation.
- Monitor the 2022 behavioral health revenue figures to determine if the $5.0 million earn-out is triggered.
- Review the specific revenue targets required for the performance-based vesting of Ritvik Singh's stock options.
- Check for any subsequent filings regarding the release of the $3.0 million hold-back funds after the 18-month period.